Skip to main content
. 2014 May 20;16(8):1100–1109. doi: 10.1093/neuonc/nou085

Table 1.

Patient and tumor characteristics

Parameters n
Spontaneous VDE (mm/y)
IDH1 Mutation Status
Mean ± SD Median Range P IDH1 + IDH1− P
Clinical parameters
Sex 131 .592 .477
 Male 79 5.2 ± 4.4 3.7 0–22.6 79.8% 20.2
 Female 52 5.7 ± 6.8 3.8 0–31.0 84.6 15.4
Age 131 .887 .031
 <40 75 5.8 ± 6.4 3.7 0–31.0 88.0 12.0
 ≥40 56 4.9 ± 4.0 3.9 0–19.2 73.2 18.3
Increased intracranial pressure 109 .973 .343
 Yes 2 11.0 ± 15.8 11.0 0–31.0 50.0 50.0
 No 107 5.0 ± 5.1 3.6 0–22.0 80.4 19.6
Neurological deficit 109 .271 .180
 Yes 20 6.5 ± 7.0 4.6 0–27.9 90.0 10.0
 No 89 4.8 ± 4.9 3.5 0–31.0 77.5 22.5
Seizures 109 .156 .365
 Yes 78 5.6 ± 5.9 3.1 0–31.0 82.1 17.9
 No 31 3.8 ± 3.2 3.8 0–15.0 74.2 25.8
KPS 131 .005 .114
 >70% 125 5.1 ± 5.3 3.7 0–31.0 80.8 19.2
 ≤70% 6 11.4 ± 6.6 9.9 4.7–22.0 100.0 0
Imaging parameters
Cerebral lobes involved 118 .119 .054
 <2 79 4.8 ± 5.3 3.5 0–31.0 88.6 11.4
 ≥2 39 6.5 ± 5.7 4.7 0–22.6 74.4 25.6
Corpus callosum involvement 117 .434 .410
 No 105 5.0 ± 5.3 3.7 1.1–31.0 84.8 15.2
 Yes 12 7.6 ± 7.0 6.8 0–22.6 75.0 25.0
Tumor location 131 .666 .509
 Frontal 62 5.2 ± 5.9 3.4 0–31.0 80.7 19.4
 Temporal 22 6.7 ± 7.1 3.9 0–28.0 77.3 22.7
 Insular 31 5.0 ± 3.5 4.7 0.4–14.2 80.7 19.3
 Parietal 16 5.1 ± 4.1 3.7 0.6–16.9 93.8 6.2
Contrast enhancement 131 .582 .449
 No 121 5.2 ± 5.0 3.8 0–31.0 81.0 19.0
 Yes 10 7.5 ± 9.9 2.4 0–27.9 90.0 10.0
Tumor volume 131 .778 .589
 <100 cc 104 5.2 ± 5.3 5.8 0–31.0 80.8 19.2
 ≥100 cc 27 6.4 ± 6.1 3.6 0–22.6 85.2 14.8
Spontaneous VDE 131 .898
 <8 mm/y 108 81.5 18.5
 ≥8 mm/y 23 82.6 17.4
Histopathological and molecular parameters
Histopathological diagnosis 131 .536 .087
 Astrocytoma 25 5.5 ± 5.5 4.0 0.4–27.9 72.0 28.0
 Oligodendroglioma 71 5.3 ± 5.8 3.7 0–31.0 88.6 11.4
 Mixed glioma 35 5.6 ± 4.9 4.6 0–22.9 75.0 25.0
Oligodendroglial component 131 .526 .222
 Yes 106 5.4 ± 5.5 3.7 0–31.0 83.8 18.2
 No 25 5.5 ± 5.5 4.0 0.4–27.9 72.0 28.0
Proliferation rates 115 .888 .914
 <5% 70 5.4 ± 5.9 3.5 0–31.0 81.4 18.6
 ≥5% 45 5.1 ± 4.7 3.7 0–22.0 82.2 17.8
1p19q Codeletion 119 .077 .497
 Yes 38 5.0 ± 6.0 3.1 0–31.0 79.0 20.1
 No 81 5.6 ± 5.0 4.4 0–27.9 84.2 15.8
p53 Overexpression 125 .202 .250
 Yes 65 5.8 ± 5.2 4.4 0–27.9 86.2 13.8
 No 60 5.0 ± 5.6 3.5 0–31.0 78.3 21.7
IDH1 mutation 131 .823
 Yes 107 5.4 ± 5.6 3.8 0–31.0
 No 24 5.2 ± 5.0 3.8 0–19.2
First-line oncological treatments
Surgical resection 131 .236 .574
 Yes 83 4.5 ± 4.2 3.6 0–31.0 83.1 16.9
 No 48 6.8 ± 6.9 4.0 0.5–27.9 79.2 20.8
Extent of surgical resection 131 .396 .339
 Biopsy 48 6.9 ± 7.7 4.0 0.5–27.9 79.2 20.8
 Partial removal 16 4.4 ± 3.2 3.7 0–12.3 87.5 12.5
 Subtotal removal 49 4.5 ± 3.1 4.0 0–15.0 83.7 16.3
 Total removal 18 4.8 ± 7.1 3.2 0–31.0 77.8 22.2
Radiation therapy 131 .467 .158
 Yes 23 6.7 ± 5.8 4.5 0.6–22.6 91.3 8.7
 No 108 5.1 ± 5.4 3.6 0–31.0 79.6 20.4
Chemotherapy 131 .040 .099
 Yes 14 3.7 ± 4.6 2.6 0.4–19.2 64.3 35.7
 No 117 5.6 ± 5.5 4.0 0–31.0 83.8 16.2

Boldface indicates statistically significant.